ProfoundBio
Seattle
About ProfoundBio
ProfoundBio is a clinical-stage biotechnology company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on internally developed, innovative, and proprietary technology platforms, ProfoundBio has developed a pipeline consisting of multiple antibody-drug conjugate (ADC) drug candidates targeting solid tumors and hematological malignancies that are in discovery, preclinical, and clinical development stages.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $247.0M
- Funding stage: M&A
- Last round: Series B (Feb 2024)
- Website: profoundbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/profoundbio-124055 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.